Aspirin v placebo for primary prevention of coronary artery disease*
| Weighted event rates | ||||
|---|---|---|---|---|
| Outcomes at 3.8 to 6.8 years | Aspirin | Placebo | RRR (95% CI) | NNT (CI) |
| Myocardial infarction | 1.7% | 2.4% | 30% (20 to 38) | 150 (113 to 224) |
| All cardiovascular events | 4.5% | 5.2% | 13% (6 to 19) | 149 (97 to 317) |
| All-cause mortality | 3.2% | 3.4% | 6% (−3 to 14) | Not significant |
| RRI (CI) | NNH (CI) | |||
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in original articles. | ||||
| Stroke | 1.5% | 1.4% | 5% (−22 to 9) | Not significant |
| Bleeding complications | 1.0% | 0.7% | 63% (34 to 99) | 375 (251 to 739) |